Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03579875 · ClinicalTrials.gov registry record · Phase 2
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
A Phase 2 study of Myelodysplastic Syndromes and Severe Aplastic Anemia, sponsored by Masonic Cancer Center, University of Minnesota.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT03579875 is a Phase 2 study of Myelodysplastic Syndromes and Severe Aplastic Anemia that is actively recruiting participants, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 48 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03579875, a Phase 2 study of Myelodysplastic Syndromes and Severe Aplastic Anemia, is actively recruiting participants, sponsored by Masonic Cancer Center, University of Minnesota.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase II trial of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation in patients with inherited bone marrow failure (BMF) disorders to eliminate the need for routine graft-versus-host disease (GVHD) immune suppression leading to earlier immune recovery and potentially a reduction in the risk of severe infections after transplantation.
Conditions Studied
Interventions
- DRUG Total Body Irradiation (TBI) (Plan 1)
- DRUG Cyclophosphamide (CY) (Plan 1)
- DRUG Fludarabine (FLU)
- DRUG Methylprednisolone (MP)
- DEVICE Donor mobilized PBSC infusion
Study Locations (1)
Minnesota
- Masonic Cancer Center at University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2018-11-13 |
| Est. Completion | 2029-01-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03579875
The ClinicalTrials.gov registry entry for NCT03579875 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (83% lower). The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 5 interventions - of which Total Body Irradiation (TBI) (Plan 1) is the first listed.
NCT03579875 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT03579875 about?
NCT03579875 is a clinical study titled "Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders". This is a phase II trial of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation in patients with inherited bone marrow failure (BMF) disorders to eliminate the need for routine graft-versus-host disease (GVHD) immune suppression leading to earlier immune ...
What is the current status of trial NCT03579875?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2018-11-13. Estimated completion is 2029-01-05.
What conditions does trial NCT03579875 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Severe Aplastic Anemia, Fanconi Anemia, Dyskeratosis Congenita, Bone Marrow Failure.
What interventions are being tested in trial NCT03579875?
The interventions under investigation include: Total Body Irradiation (TBI) (Plan 1) (DRUG), Cyclophosphamide (CY) (Plan 1) (DRUG), Fludarabine (FLU) (DRUG), Methylprednisolone (MP) (DRUG), Donor mobilized PBSC infusion (DEVICE).
Who is sponsoring clinical trial NCT03579875?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03579875 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 2
-
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
RECRUITING · Phase 2
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Ascorbate in Myelodysplastic Syndrome
RECRUITING · Phase 2
-
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.